Everson R B, Griffin F M, Capizzi R L
Mutat Res. 1985 Dec;147(6):369-78. doi: 10.1016/0165-1161(85)90006-8.
We investigated the likelihood that human peripheral blood mononuclear cells which incorporate tritiated thymidine in the presence of 6-thioguanine (6-TG) are mutants by comparing findings for cells from the same blood specimen cultured in the presence or absence of phytohemagglutinin (PHA). After 42 h in culture, autoradiography revealed that about 0.1% of cells from healthy control donors and 1% of cells from patients receiving chemotherapy for breast cancer labeled in the absence of PHA. About 5% of this number labeled when 6-TG was added to the medium. This high frequency of cells labeling in the presence of 6-TG suggested that many cells were resistant to 6-TG for reasons other than mutation at the HGPRT locus. Despite a labeling index of about 30% in the presence of PHA alone, the addition of PHA to cells cultured with 6-TG did not increase the labeling index over that observed with 6-TG alone. Also, in the presence of 6-TG there was a significant correlation between labeling indices for cells from the same blood specimen cultured with or without PHA. These findings suggest that the two conditions measured the same population of non-mutant cells. These studies reinforce observations made by the developers of this technique and other laboratories which indicate that refinements will be required before the assay can be used to study somatic cell mutation in human populations. Such refinements are underway in several laboratories; although not definitive, the approach and procedures used in this report which investigated the original assay procedure provide methods and criteria to judge whether modifications of assay techniques improve the quantification of in vivo human somatic cell mutation.
我们通过比较在有或没有植物血凝素(PHA)的情况下培养的来自同一血液样本的细胞的结果,研究了在6-硫鸟嘌呤(6-TG)存在下掺入氚标记胸腺嘧啶核苷的人外周血单核细胞是突变体的可能性。培养42小时后,放射自显影显示,在没有PHA的情况下,来自健康对照供体的约0.1%的细胞和接受乳腺癌化疗的患者的1%的细胞被标记。当向培养基中添加6-TG时,这个数字的约5%被标记。在6-TG存在下如此高频率的细胞标记表明,许多细胞对6-TG耐药的原因并非是次黄嘌呤鸟嘌呤磷酸核糖转移酶(HGPRT)位点的突变。尽管仅在PHA存在下标记指数约为30%,但将PHA添加到用6-TG培养的细胞中并没有使标记指数比仅用6-TG观察到的增加。此外,在6-TG存在的情况下,来自同一血液样本的细胞在有或没有PHA培养时的标记指数之间存在显著相关性。这些发现表明,这两种情况测量的是同一群体的非突变细胞。这些研究强化了该技术开发者和其他实验室的观察结果,即该检测方法在用于研究人类群体中的体细胞突变之前需要改进。几个实验室正在进行这样的改进;尽管尚无定论,但本报告中用于研究原始检测程序的方法和程序为判断检测技术的修改是否改善了体内人类体细胞突变的定量提供了方法和标准。